Pediatric Endocrinology Diabetes and Metabolism

Niedobór dehydrogenazy acylo-CoA średniołańcuchowych kwasów tłuszczowych w okresie noworodkowym – opis przypadku

Aleksandra Wądołowska 1
,
Magdalena Alicja Suda-Całus 1
,
Ewa Matylda Gulczyńska 1

  1. Department of Neonatology, Neonatal Intensive Care Unit and Neonatal Pathology, Polish Mother’s
    Memorial Hospital – Research Institute, Łódz, Poland

Pediatr Endocrinol Diabetes Metab 2026; 32 (3):

DOI: https://doi.org/10.5114/pedm.2026.163264
Data publikacji online: 2026/08/14
Plik artykułu
0400_Medium-chain.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Mason E, Hindmarch C, Dunham-Snary K. Medium-chain acyl-CoA dehydrogenase deficiency: pathogenesis, diagnosis, and treatment. Endocrinol Diabetes Metab 2022; 6: e385. doi: 10.1002/edm2.385.
  2. Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA, et al. Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 2010; 99: 263–268. doi: 10.1016/j.ymgme.2009.10.188.
  3. Sander S, Janzen N, Janetzky B, et al. Neonatal screening for medium chain acyl-CoA deficiency: high incidence in Lower Saxony (northern Germany). Eur J Pediatr 2001; 160: 318–319. doi: 10.1007/pl00008439.
  4. Gregersen N, Winter V, Curtis D, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: the prevalent mutation G985 (K304E) is subject to a strong founder effect from northwestern Europe. Hum Hered 1993; 43: 342–350. doi: 10.1159/000154157.
  5. Rodwell V, Bender D, Botham KM, et al. Biochemia Harpera. Ilustrowana. 7 ed. Warsaw: PZWL; 2018.
  6. Rhead WJ. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. J Inherit Metab Dis 2006; 29: 370–377. doi: 10.1007/s10545-006-0292-1.
  7. Matern D, Rinaldo P, Pagon RA, et al. Medium-chain acyl-coenzyme A dehydrogenase deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993–2024.
  8. Weiss KJ, Berger U, Haider M, et al. Free carnitine concentrations and biochemical parameters in medium-chain acyl-CoA dehydrogenase deficiency: genotype-phenotype correlation. Clin Genet 2023; 103: 644-654. doi: 10.1111/cge.14316.
  9. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405–424. doi: 10.1038/gim.2015.30.
  10. Rizzo JM, Buck MJ. Key principles and clinical applications of “next-generation” DNA sequencing. Cancer Prev Res (Phila) 2012; 5: 887–900. doi: 10.1158/1940-6207.CAPR-11-0432.
  11. Grosse SD, Khoury MJ, Greene CL, et al. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 2006; 8: 205–212. doi: 10.1097/01.gim.0000204472.25153.8d.
  12. Chang I, Lam C, Vockley J. Medium-chain acyl-coenzyme a dehydrogenase deficiency. Avaible at: https://www.ncbi.nlm.nih.gov/books/NBK1424/ (Accessed 20 Jul 2025).
  13. Ibrahim S, Temtem T. Medium-chain acyl-CoA dehydrogenase deficiency. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
  14. Iafolla A, Thompson R, Roe C. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994; 124: 409–415. doi: 10.1016/s0022-3476(94)70363-9.
  15. Baruteau J, Levade T, Redonnet-Vernhet I, et al. Hypoketotic hypoglycemia with myolysis and hypoparathyroidism: an unusual association in medium chain acyl-CoA desydrogenase deficiency (MCADD). J Pediatr Endocrinol Metab 2009; 22: 1175–1177.
  16. Yusupov R, Finegold DN, Naylor EW, et al. Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency (MCADD) despite newborn screening. Mol Genet Metab 2010; 101: 33–39. doi: 10.1016/j.ymgme.2010.05.007.
  17. Baruteau J, Sachs P, Broue P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis 2013; 36: 795–803. doi: 10.1007/s10545-012-9542-6.
  18. McGregor TL, Berry SA, Dipple KM, Hamid R. Management principles for acute illness in patients with medium-chain acyl-coenzyme A dehydrogenase deficiency. Pediatrics. 2021; 147: e2020040303. doi: 10.1542/peds.2020-040303.
  19. Maguolo A, Rodella G, Dianin A, et al. Diagnosis, genetic characterization and clinical follow up of mitochondrial fatty acid oxidation disorders in the new era of expanded newborn screening: a single centre experience. Mol Genet Metab Rep 2020; 24: 100632. doi: 10.1016/j.ymgmr.2020.100632.
  20. Kormanik K, Kang H, Cuebas D, et al. Evidence for involvement of medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate. Mol Genet Metab 2012; 107: 684–689. doi: 10.1016/j.ymgme.2012.10.009.
  21. Schowalter DB, Matern D, Vockley J. In vitro correction of medium chain acyl CoA dehydrogenase deficiency with a recombinant adenoviral vector. Mol Genet Metab 2005; 85: 88–95. doi: 10.1016/j.ymgme.2005.02.006.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
Zintergrowane z
integrated with publons
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications